Bibiliografía

Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Renal Impairment, Recurrent Venous Thromboembolism and bleeding in cancer with acute venous thromboembolism. Analysis of the CATCH Study. Thromb Haemost. 2018 May;118(5):914-21. [PubMed]

Chronic kidney disease: assessment and management. London: National Institute for Health and Care Excellence (NICE); 2021 Nov 24. [PubMed]

Di Micco P, Monreal M. Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry. J Blood Med. 2019 Dec 31;10:453-6. [PubMed]

Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol. 2015 Apr;22(2):144-55. [PubMed]

Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015 Apr;22(2):133-43. [PubMed]

Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al.; ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023 May;34(5):452-67. [PubMed]

Falgá C, Capdevila JA, Soler S, Rabuñal R, Sánchez Muñoz-Torrero JF, Gallego P, Monreal M; RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost. 2007 Oct; 98(4):771-6. [PubMed]

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. [PubMed]

Hornung P, Khairoun M, Dekker FW, Kaasjager KAH, Huisman A, Jakulj L, et al. Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes. PLoS One. 2020 Oct 1;15(10):e0239222. [PubMed]

Jiménez-Fonseca P, Gallardo E, Arranz Arija F, Blanco JM, Callejo A, Lavin DC, et al. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. Eur J Intern Med. 2022 Jun;100:33-45. [PubMed]

Knueppel P, Bang SH, Troyer C, Barriga A, Shin J, Cadiz CL, et al. Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). Thromb Res. 2022 Dec;220:91-6. [PubMed]

Kooiman J, den Exter PL, Cannegieter SC, le Cessie S, del Toro J, Sahuquillo JC, et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost. 2013 Nov;11(11): 968-76. [PubMed]

Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al.; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer. 2007 Sep 15;110(6):1376-84. [PubMed]

Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 May 2;144(9):673-84. [PubMed]

Malyszko J, Tesarova P, Capasso G, Capasso A. The link between kidney disease and cancer: complications and treatment. Lancet. 2020 Jul 25;396(10246):277-87. . [PubMed]

Pachón V, Trujillo-Santos J, Domènech P, Gallardo E, Font C, González-Porras JR, et al. Cancer- Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM- SETH) Expert Consensus. TH Open. 2018 Nov 5;2(4):e373-e386. [PubMed]

Ribic C, Crowther M. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):188-95. [PubMed]

Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis. 2017 Sep;11(9):243-56. [PubMed]

Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F. A post-hoc analysis of dalteparin verus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment. J Thromb Thrombolysis. 2016 Nov;42(4):494-504. [PubMed]